Capital Insight Partners’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-13,873
| Closed | -$1.18M | – | 34 |
|
|
2025
Q4 | $1.18M | Sell |
13,873
-25,203
| -64% | -$2.07M | 0.25% | 78 |
|
|
2025
Q3 | $3.04M | Sell |
39,076
-10,231
| -21% | -$799K | 0.5% | 59 |
|
|
2025
Q2 | $3.86M | Sell |
49,307
-8,108
| -14% | -$605K | 0.67% | 46 |
|
|
2025
Q1 | $4.16M | Sell |
57,415
-5,077
| -8% | -$363K | 0.73% | 46 |
|
|
2024
Q4 | $4.63M | Buy |
62,492
+2,164
| +4% | +$151K | 0.8% | 43 |
|
|
2024
Q3 | $3.98M | Buy |
60,328
+4,290
| +8% | +$312K | 0.7% | 52 |
|
|
2024
Q2 | $5.18M | Sell |
56,038
-459
| -0.8% | -$40.6K | 0.98% | 35 |
|
|
2024
Q1 | $5.4M | Buy |
56,497
+6,602
| +13% | +$555K | 1.01% | 29 |
|
|
2023
Q4 | $3.8M | Buy |
49,895
+1,589
| +3% | +$111K | 0.78% | 45 |
|
|
2023
Q3 | $3.35M | Buy |
48,306
+2,546
| +6% | +$205K | 0.76% | 45 |
|
|
2023
Q2 | $4.32M | Sell |
45,760
-163
| -0.4% | -$14.2K | 0.97% | 28 |
|
|
2023
Q1 | $3.8M | Buy |
45,923
+891
| +2% | +$70K | 0.89% | 34 |
|
|
2022
Q4 | $3.36M | Buy |
45,032
+1,267
| +3% | +$97.6K | 0.87% | 34 |
|
|
2022
Q3 | $3.62M | Buy |
43,765
+607
| +1% | +$58.4K | 0.97% | 29 |
|
|
2022
Q2 | $4.1M | Buy |
43,158
+314
| +0.7% | +$32.5K | 0.96% | 29 |
|
|
2022
Q1 | $5.04M | Buy |
42,844
+2,572
| +6% | +$289K | 1.03% | 23 |
|
|
2021
Q4 | $5.22M | Buy |
40,272
+846
| +2% | +$98.7K | 1.06% | 25 |
|
|
2021
Q3 | $4.46M | Sell |
39,426
-16
| -0% | -$1.83K | 0.97% | 29 |
|
|
2021
Q2 | $4.08M | Buy |
39,442
+1,007
| +3% | +$94.9K | 0.92% | 31 |
|
|
2021
Q1 | $3.21M | Buy |
38,435
+1,813
| +5% | +$153K | 0.78% | 39 |
|
|
2020
Q4 | $3.34M | Buy |
36,622
+588
| +2% | +$48.8K | 0.84% | 37 |
|
|
2020
Q3 | $2.88M | Buy |
36,034
+33
| +0.1% | +$2.58K | 0.81% | 39 |
|
|
2020
Q2 | $2.49M | Buy |
36,001
+670
| +2% | +$47.6K | 0.78% | 41 |
|
|
2020
Q1 | $2.22M | Buy |
35,331
+3,390
| +11% | +$244K | 1.17% | 25 |
|
|
2019
Q4 | $2.48M | Sell |
31,941
-468
| -1% | -$36.5K | 1.14% | 24 |
|
|
2019
Q3 | $2.38M | Sell |
32,409
-750
| -2% | -$52.7K | 2.08% | 13 |
|
|
2019
Q2 | $2.04M | Buy |
33,159
+129
| +0.4% | +$7.8K | 1.77% | 20 |
|
|
2019
Q1 | $2.11M | Buy |
33,030
+159
| +0.5% | +$9.07K | 1.9% | 17 |
|
|
2018
Q4 | $1.68M | Buy |
32,871
+144
| +0.4% | +$7.29K | 1.73% | 24 |
|
|
2018
Q3 | $1.9M | Buy |
+32,727
| New | +$1.6M | 1.67% | 26 |
|
Other funds holding EW
VCM
VPM
Capital Insight Partners's EW Position: Q1 2026 in Review
Capital Insight Partners sold out of Edwards Lifesciences (EW) in Q1 2026, closing a stake of 13,873 shares — an estimated $1.18M sold.
Capital Insight Partners first reported a position in EW in Q3 2018 and held it in 30 quarters. The position peaked at $5.4M in Q1 2024. 1,285 funds tracked by Wall St. Rank hold EW as of Q1 2026.
- Capital Insight Partners reported no remaining Edwards Lifesciences position as of Q1 2026 after selling out during the quarter.
- Capital Insight Partners sold 13,873 Edwards Lifesciences shares in Q1 2026, an estimated $1.18M.
- Capital Insight Partners first reported a position in Edwards Lifesciences in Q3 2018 and held it in 30 quarters.
- Capital Insight Partners's Edwards Lifesciences position peaked at $5.4M in Q1 2024.
- 1,285 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.
Based on Capital Insight Partners's 13F filing for Q1 2026.